3,6-Disubstituted xanthylium salts

Scott Clunas; John Mervyn David Storey; David Horsley; Janet Elizabeth Rickard; Charles Robert Harrington; Claude Michel Wischik

3,6-Disubstituted xanthylium salts

Scott Clunas (Inventor), John Mervyn David Storey (Inventor), David Horsley (Inventor), Janet Elizabeth Rickard (Inventor), Charles Robert Harrington (Inventor), Claude Michel Wischik (Inventor)

Research output: Patent

Abstract

This invention pertains generally to processes, uses, methods and materials utilising
particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer’s disease.

Original language	English
IPC	WO2010/067078
Publication status	Published - 17 Jun 2010

Development of treatments & diagnostics for Alzheimer’s disease
John Storey (Coordinator)
Impact: Other Impacts

Cite this

@misc{bbd3cbc683cd4a6faa5bade200e33de1,

title = "3,6-Disubstituted xanthylium salts",

abstract = "This invention pertains generally to processes, uses, methods and materials utilisingparticular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer{\textquoteright}s disease.",

author = "Scott Clunas and Storey, {John Mervyn David} and David Horsley and Rickard, {Janet Elizabeth} and Harrington, {Charles Robert} and Wischik, {Claude Michel}",

year = "2010",

month = jun,

day = "17",

language = "English",

type = "Patent",

note = "WO2010/067078",

}

TY - PAT

T1 - 3,6-Disubstituted xanthylium salts

AU - Clunas, Scott

AU - Storey, John Mervyn David

AU - Horsley, David

AU - Rickard, Janet Elizabeth

AU - Harrington, Charles Robert

AU - Wischik, Claude Michel

PY - 2010/6/17

Y1 - 2010/6/17

N2 - This invention pertains generally to processes, uses, methods and materials utilisingparticular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer’s disease.

AB - This invention pertains generally to processes, uses, methods and materials utilisingparticular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer’s disease.

M3 - Patent

ER -

3,6-Disubstituted xanthylium salts

Abstract

Fingerprint

Impacts

Development of treatments & diagnostics for Alzheimer’s disease

Cite this